Peptic ulcer in nephrotic syndrome patients due to steroid therapy
Abstract
Peptic ulcers comprise gastric and duodenal ulcers. Complications of peptic ulcers include bleeding, perforation, and obstruction. Bleeding is a major problem of peptic ulcers, as it is at times fatal. Peptic ulcer bleeding is diagnosed and treated by upper gastrointestinal (GI) endoscopy. Oral glucocorticosteroids (referred to hereafter as corticosteroids) are commonly prescribed for symptom control in patients receiving palliative care. A recent study has shown that one-third of patients admitted to an inpatient hospice unit were receiving corticosteroids. This frequency in prescribing exposes a large number of patients to the potential side effects known to be associated with corticosteroids, including weight gain, impaired glucose tolerance, and proximal myopathy.H. pylori infection is a risk factor for PUD in aspirin and NSAID users.
Downloads
References
Alhazzani, W., Alenezi, F., Jaeschke, R. Z., Moayyedi, P., & Cook, D. J. (2013). Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Critical care medicine, 41(3), 693–705.
Bahadur, S., Keshri, L., & Pathak, K. (2011). Adverse drug reactions and safety considerations of NSAIDs: clinical analysis. Current drug safety, 6(5), 310–317.
Bruera, E., Roca, E., Cedaro, L., Carraro, S., & Chacon, R. (1985). Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer treatment reports, 69(7-8), 751–754.
Carpani de Kaski, M., Rentsch, R., Levi, S., & Hodgson, H. J. (1995). Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Gut, 37(5), 613–616.
Conn, H. O., & Blitzer, B. L. (1976). Nonassociation of adrenocorticosteroid therapy and peptic ulcer. The New England journal of medicine, 294(9), 473–479.
da Mota, L. M., Laurindo, I. M., & dos Santos Neto, L. L. (2010). Prospective evaluation of the quality of life in a cohort of patients with early rheumatoid arthritis. Revista brasileira de reumatologia, 50(3), 249–261.
Gabriel, S. E., Jaakkimainen, L., & Bombardier, C. (1991). Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Annals of internal medicine, 115(10), 787–796.
Grahame-Smith DG, Aronson JK. The Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 1984.
Grateau, G., Hentgen, V., Stojanovic, K. S., Jéru, I., Amselem, S., & Steichen, O. (2013). How should we approach classification of autoinflammatory diseases?. Nature reviews. Rheumatology, 9(10), 624–629.
Guslandi, M., & Tittobello, A. (1992). Steroid ulcers: a myth revisited. BMJ (Clinical research ed.), 304(6828), 655–656.
Hanks, G. W., Trueman, T., & Twycross, R. G. (1983). Corticosteroids in terminal cancer--a prospective analysis of current practice. Postgraduate medical journal, 59(697), 702–706.
Hernandez-Diaz, S., & Rodriguez, L. A. (2000). Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Archives of internal medicine, 160(14), 2093–2099.
Huang, J. Q., Sridhar, S., & Hunt, R. H. (2002). Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet (London, England), 359(9300), 14–22.
Huang, T. C., & Lee, C. L. (2014). Diagnosis, treatment, and outcome in patients with bleeding peptic ulcers and Helicobacter pylori infections. BioMed research international, 2014, 658108.
Ellershaw, J. E., & Kelly, M. J. (1994). Corticosteroids and peptic ulceration. Palliative medicine, 8(4), 313–319.
Kim, S. Y., Hyun, J. J., Jung, S. W., & Lee, S. W. (2012). Management of non-variceal upper gastrointestinal bleeding. Clinical endoscopy, 45(3), 220–223.
Hsiang, K. W., Ng, Y. Y., Lu, C. L., Chen, T. S., Lin, H. Y., Luo, J. C., Wu, J. M., Lin, H. C., Chang, F. Y., & Lee, S. D. (2010). Corticosteroids therapy and peptic ulcer disease in nephrotic syndrome patients. British Journal of Clinical Pharmacology, 70(5), 756–761.
Leontiadis, G. I., Molloy-Bland, M., Moayyedi, P., & Howden, C. W. (2013). Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. The American journal of gastroenterology, 108(3), 331–346.
Luo, J. C., Chang, F. Y., Chen, T. S., Ng, Y. Y., Lin, H. C., Lu, C. L., Chen, C. Y., Lin, H. Y., & Lee, S. D. (2009). Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. British journal of clinical pharmacology, 68(2), 252–259.
Luo, J. C., Chang, F. Y., Lin, H. Y., Lu, R. H., Lu, C. L., Chen, C. Y., & Lee, S. D. (2002). The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. Alimentary pharmacology & therapeutics, 16(7), 1241–1248.
Luo, J. C., Shin, V. Y., Liu, E. S., So, W. H., Ye, Y. N., Chang, F. Y., & Cho, C. H. (2003). Non-ulcerogenic dose of dexamethasone delays gastric ulcer healing in rats. The Journal of pharmacology and experimental therapeutics, 307(2), 692–698.
Luo, J. C., Shin, V. Y., Liu, E. S., Ye, Y. N., Wu, W. K., So, W. H., Chang, F. Y., & Cho, C. H. (2004). Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. European journal of pharmacology, 485(1-3), 275–281.
Martinek, J., Hlavova, K., Zavada, F., Seifert, B., Rejchrt, S., Urban, O., & Zavoral, M. (2010). "A surviving myth"--corticosteroids are still considered ulcerogenic by a majority of physicians. Scandinavian journal of gastroenterology, 45(10), 1156–1161.
Milosavljevic, T., Kostic-Milosavljevic, M., Jovanovic, I., & Krstic, M. (2011). Complications of peptic ulcer disease. Digestive diseases (Basel, Switzerland), 29(5), 491–493.
Needham, P. R., Daley, A. G., & Lennard, R. F. (1992). Steroids in advanced cancer: survey of current practice. BMJ (Clinical research ed.), 305(6860), 999.
Radner, H., Yoshida, K., Mjaavatten, M. D., Aletaha, D., Frits, M., Lu, B., Iannaccone, C., Shadick, N., Weinblatt, M., Hmamouchi, I., Dougados, M., Smolen, J. S., & Solomon, D. H. (2015). Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. Seminars in arthritis and rheumatism, 45(2), 167–173.
Sugimoto, M., Sakai, K., Kita, M., Imanishi, J., & Yamaoka, Y. (2009). Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney international, 75(1), 96–103.
Tuskey, A., & Peura, D. (2013). The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis research & therapy, 15 Suppl 3(Suppl 3), S6.
van der Goes, M. C., Jacobs, J. W., & Bijlsma, J. W. (2014). The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. Arthritis research & therapy, 16 Suppl 2(Suppl 2), S2.
Copyright (c) 2023 Sreeja Ankireddypalli
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
